Alcon Inc. (ALC)
| Market Cap | 42.30B |
| Revenue (ttm) | 9.93B |
| Net Income (ttm) | 1.12B |
| Shares Out | 495.70M |
| EPS (ttm) | 2.25 |
| PE Ratio | 37.76 |
| Forward PE | 26.08 |
| Dividend | $0.33 (0.39%) |
| Ex-Dividend Date | May 13, 2025 |
| Volume | 1,990,480 |
| Open | 85.46 |
| Previous Close | 85.38 |
| Day's Range | 85.09 - 86.91 |
| 52-Week Range | 80.48 - 101.10 |
| Beta | 0.75 |
| Analysts | Buy |
| Price Target | 107.00 (+23.91%) |
| Earnings Date | May 13, 2025 |
About ALC
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. It operates through two segments, Surgical and Vision Care. The company offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. Its cataract products include Centurion vision system, LenSx laser system, Verion reference unit and Verion digital marker, ... [Read more]
Financial Performance
In 2024, Alcon's revenue was $9.91 billion, an increase of 4.82% compared to the previous year's $9.46 billion. Earnings were $1.02 billion, an increase of 4.52%.
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for ALC stock is "Buy." The 12-month stock price forecast is $107.0, which is an increase of 23.91% from the latest price.
News
US FDA approves Alcon's new dry-eye drug
Eye-care drugmaker Alcon said on Wednesday that the U.S. Food and Drug Administration has approved its treatment for dry eye disease (DED).
Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease
GENEVA--(BUSINESS WIRE)--Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease.
Turkey Contact Lens Market - Competition, Forecast & Opportunities to 2030, Featuring Tech Contactlens, Diafarma, Alcon Laboratories, Diplomat Optics, Hoya Turkiye, ZEISS Turkiye, Keralens & more
The Turkish Contact Lens Market, valued at USD 55.15 Million in 2024, is set to reach USD 91.08 Million by 2030, at a CAGR of 8.68%. Growth is driven by rising vision correction awareness and demand f...
Alcon Inc. (ALC) Q1 2025 Earnings Call Transcript
Alcon Inc. (NYSE:ALC) Q1 2025 Earnings Conference Call May 14, 2025 8:00 AM ET Company Participants Dan Cravens - Vice President, Investor Relations David Endicott - Chief Executive Officer Tim Stone...
Alcon, American Eagle, GRAIL And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Wednesday.
Alcon Reports First-Quarter 2025 Results and Launches Transformational Change in Ophthalmic Surgery with Unity VCS
GENEVA--(BUSINESS WIRE)--Alcon Reports First-Quarter 2025 Results and Launches Transformational Change in Ophthalmic Surgery with Unity VCS.
Alcon Announces Results of 2025 Annual General Meeting
GENEVA--(BUSINESS WIRE)--Alcon Announces Results of 2025 Annual General Meeting.
Alcon Elevates Vitreoretinal and Cataract Surgery for Superior Efficiency* with UNITY VCS and UNITY CS
GENEVA--(BUSINESS WIRE)--Alcon Elevates Vitreoretinal and Cataract Surgery for Superior Efficiency* with UNITY VCS and UNITY CS.
Alcon Publishes Agenda for 2025 Annual General Meeting
GENEVA--(BUSINESS WIRE)--Alcon Publishes Agenda for 2025 Annual General Meeting.
Alcon Expands Leadership in IOL Innovation with Clareon PanOptix Pro, Delivering Best-in-Class Light Utilization and Less Light Scatter
GENEVA--(BUSINESS WIRE)--Alcon Expands Leadership in IOL Innovation with Clareon PanOptix Pro, Delivering Best-in-Class Light Utilization and Less Light Scatter.
Alcon Acquires Majority Interest in Aurion Biotech, Inc. to Advance Innovative Cell Therapy for Corneal Endothelial Disease
GENEVA--(BUSINESS WIRE)--Alcon Acquires Majority Interest in Aurion Biotech, Inc. to Advance Innovative Cell Therapy for Corneal Endothelial Disease.
LENSAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of LENSAR, Inc. - LNSR
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of LENSA...
Alcon Announces CE Mark Approval and Commercialization of Clareon Vivity IOL in Europe, Expanding Visual Possibilities
GENEVA--(BUSINESS WIRE)--Alcon Announces CE Mark Approval and Commercialization of Clareon Vivity IOL in Europe, Expanding Visual Possibilities.
Alcon Agrees to Acquire LENSAR, Inc.
GENEVA, Switzerland & ORLANDO, Fla.--(BUSINESS WIRE)--Alcon Agrees to Acquire LENSAR, Inc.
Retinal Surgery Devices Market Outlook Report 2025-2033: Revenues Set to Double, Reaching $4.83 Billion by 2033, Led by Topcon Corp., Alcon, and Carl Zeiss
Dublin, March 24, 2025 (GLOBE NEWSWIRE) -- The "Retinal Surgery Devices Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033" has been added to ResearchAndMarkets.com's offerin...
Alcon to Host 2025 Capital Markets Day
GENEVA--(BUSINESS WIRE)--Alcon to Host 2025 Capital Markets Day.
Alcon Canada Strengthens its Commitment to Astigmatic Patients with TOTAL30 for Astigmatism Expanded Parameters
TORONTO--(BUSINESS WIRE)--Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the availability of expanded parameters for TOTAL30® for Ast...
Watch CNBC's full interview with Alcon CEO David Endicott
Alcon CEO David Endicott discusses the pharmaceutical firm's full-year results.
Alcon Inc. (ALC) Q4 2024 Earnings Call Transcript
Alcon Inc. (NYSE:ALC) Q4 2024 Earnings Conference Call February 26, 2025 8:00 AM ET Company Participants Dan Cravens - Vice President, Investor Relations David Endicott - Chief Executive Officer Tim ...
Alcon eyes revenue growth in 2025 after in-line results
Alcon forecast sales of between $10.2 and $10.4 billion for 2025, after the eye care group reported higher fourth-quarter revenue underpinned by its surgical division on Tuesday.
Alcon Reports Full-Year 2024 Results, with Strong Top-line and Earnings Growth and Record Cash Generation
GENEVA--(BUSINESS WIRE)--Alcon Reports Full-Year 2024 Results, with Strong Top-line and Earnings Growth and Record Cash Generation.
Alcon Announces U.S. Launch of New SYSTANE PRO Preservative-Free, Revolutionizing Dry Eye Relief With Its Longest Lasting Formula Yet
GENEVA--(BUSINESS WIRE)--Alcon Announces U.S. Launch of New SYSTANE PRO Preservative-Free, Revolutionizing Dry Eye Relief with Its Longest Lasting Formula Yet.
Alcon Announces U.S. Launch of Voyager DSLT, First-of-its-Kind Treatment for Glaucoma and Ocular Hypertension
GENEVA--(BUSINESS WIRE)--Alcon Announces U.S. Launch of Voyager DSLT, First-of-its-Kind Treatment for Glaucoma and Ocular Hypertension.
Alcon to Present at 2025 Annual J.P. Morgan Healthcare Conference
GENEVA--(BUSINESS WIRE)--Alcon to Present at 2025 Annual J.P. Morgan Healthcare Conference.
Alcon: Q3, Slight Guidance Cut Is Not Something Structural
I reiterate a 'Strong Buy' rating for Alcon with a one-year price target of $118 per share, despite a minor guidance cut. Alcon's new product launches, including PRECISION7 and Systane Pro, are expect...